Trial Profile
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 07 Apr 2020 Status changed from active, no longer recruiting to completed.
- 17 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.